Gemini BioProducts adds Bryan Poltilove to its Board of Directors

– USA, CA –  Gemini BioProducts Holding, Inc., today announced the appointment of Bryan Poltilove to its Board of Directors.

About Bryan Poltilove

Bryan Poltilove is an operating partner at BroadOak Capital Partners and leads the firm’s investments in cell and gene therapy, bioproduction, and cell biology. Previously, Bryan spent 12 years with Thermo Fisher Scientific, where he served as VP and GM. Bryan grew the company’s cell-and-gene therapy business organically at 50%+ CAGR and through acquisitions, including Brammer Bio. Before Thermo Fisher, Bryan served as Director of Revenue Strategy & Operations at the Corporate Executive Board and held several commercial strategy roles with Johnson & Johnson.

“I am excited to join the GeminiBio Board at such a pivotal time in the company’s evolution,” said Bryan Poltilove. “I look forward to working with the team to help execute on their growth plan.”

Bryan Poltilove holds B.S. degrees in both Chemical Engineering and Economics from the Massachusetts Institute of Technology as well as an M.B.A. from the J.L. Kellogg School of Management at Northwestern University.

About GeminiBio

GeminiBio is a portfolio company of BelHealth Investment Partners, LLC, a Florida-based healthcare private equity firm, and BroadOak Capital Partners, a life science-focused investment firm. Founded in 1985, GeminiBio serves the global biotechnology industry, from basic research to commercial production, with a focus on helping our customers accelerate the development of life-enhancing biotherapeutics by streamlining and improving their cell culture and process liquid manufacturing workflows. The company’s products are organized into two core verticals – Cell Culture Solutions and Process Liquid Solutions. Located in West Sacramento, California, GeminiBio has 57,000 square feet of cGMP manufacturing space that is segregated between animal-origin-free and animal-component manufacturing. GeminiBio is an ISO 13485 certified, FDA registered Class 1 Medical Device Manufacturer, aligned with 21 CFR Part 820.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.